nach oben

Erschienen in:

03.01.2020 | Original Article

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

verfasst von: Alessandra Battaglia, Alexia Buzzonetti, Marco Fossati, Giovanni Scambia, Andrea Fattorossi, Madi R. Madiyalakan, Yolanda D. Mahnke, Christopher Nicodemus

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

The standard-of-care (SOC) first-line therapy for ovarian cancer (OC) patients is plagued with high relapse rates. Several studies indicated the immune system’s prominent role changing the disease course in OC patients. Chemo-immunotherapy regimens, currently being explored, include oregovomab, which is a monoclonal antibody specific for the OC associated antigen carbohydrate/cancer antigen 125 (CA125) that yielded promising results when administered together with SOC in a previous study. The QPT-ORE-002 multi-site phase II randomized study demonstrated that in patients with advanced OC, oregovomab combined with first-line SOC improved overall and progression-free survival, compared to SOC alone. The study included an Italian cohort in which we demonstrated that adding oregovomab to SOC resulted in increased patient numbers with amplified CA125-specific CD8⁺T lymphocytes/ml peripheral blood counts, which might explain the improved therapeutic effect of SOC + oregovomab over SOC alone. Predictive for oregovomab efficacy was a less suppressive immune environment at baseline as indicated by low numbers of circulating myeloid-derived suppressor cells, subset type 4, and a low neutrophil-and-monocyte to lymphocyte ratio.

Nur mit Berechtigung zugänglich

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio MGR, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203–213. https://doi.org/10.1056/NEJMoa020177 CrossRefPubMed

Mariya T, Hirohashi Y, Torigoe T, Asano T, Kuroda T, Yasuda K, Mizuuchi M, Sonoda T, Saito T, Sato N (2014) Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer. Cancer Immunol Res 2(12):1220–1229. https://doi.org/10.1158/2326-6066.CIR-14-0101 CrossRefPubMed

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer. Process Natl Acad Sci USA 104(9):3360–3365. https://doi.org/10.1073/pnas.0611533104 CrossRef

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949. https://doi.org/10.1038/nm1093 CrossRefPubMed

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Process Natl Acad Sci USA 102(51):18538–18543. https://doi.org/10.1073/pnas.0509182102 CrossRef

Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL (2013) The ratios of CD8 + T cells to CD4 + CD25 + FOXP3 + and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One 8(11):e80063. https://doi.org/10.1371/journal.pone.0080063 CrossRefPubMedPubMedCentral

Paijens ST, Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, de Bruyn M, Nijman HW (2018) Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 9:CD007287. https://doi.org/10.1002/14651858.cd007287.pub4 CrossRefPubMed

Nustad K, Bast RC Jr, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Bormer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarstrom S, Kenemans P, Hilgers J (1996) Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 17(4):196–219CrossRef

Capstick V, Maclean GD, Suresh MR, Bodnar D, Lloyd S, Shepert L, Longenecker BM, Krantz M (1991) Clinical evaluation of a new two-site assay for CA125 antigen. Int J Biol Markers 6(2):129–135CrossRef

10.

Piché A (2016) Pathobiological role of MUC16 mucin (CA125) in ovarian cancer: much more than a tumor biomarker. World J Obstet Gynecol 5(1):39–49. https://doi.org/10.5317/wjog.v5.i1.39 CrossRef

11.

Noujaim AA, Schultes BC, Baum RP, Madiyalakan R (2001) Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 16(3):187–203. https://doi.org/10.1089/10849780152389384 CrossRefPubMed

12.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF (2004) Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22(17):3507–3516. https://doi.org/10.1200/jco.2004.09.016 CrossRefPubMed

13.

Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, Schoonmaker C, Whiteside T, Smith LM, Method M (2009) The Immune adjuvant properties of frontline carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 32(1):54–65. https://doi.org/10.1097/CJI.0b013e31818b3dad CrossRefPubMed

14.

Ferrandina G, Braly PS, Terranova C, Salutari V, Ricci C, Raspagliesi F, Lorusso D, Panici PB, Scollo P, Plotti F, Brewer M, Method MW, Holloway RW, Madiyalakan M, Nicodemus CF, Pecorelli SL, Scambia G, Angioli R (2017) A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in Frontline treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC). J Clin Oncol 35(15_suppl):5536. https://doi.org/10.1200/jco.2017.35.15_suppl.5536 CrossRef

15.

Marshall HT, Djamgoz MBA (2018) Immuno-oncology: emerging targets and combination therapies. Front Oncol 8:315. https://doi.org/10.3389/fonc.2018.00315 CrossRefPubMedPubMedCentral

16.

Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Tasken K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH (2015) Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother 64(10):1271–1286. https://doi.org/10.1007/s00262-015-1729-x CrossRefPubMedPubMedCentral

17.

Munn DH, Sharma MD, Johnson TS (2018) Treg destabilization and reprogramming: implications for cancer immunotherapy. Cancer Res 78(18):5191–5199. https://doi.org/10.1158/0008-5472.Can-18-1351 CrossRefPubMedPubMedCentral

18.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. https://doi.org/10.1038/nri2506 CrossRefPubMedPubMedCentral

19.

Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181(7):4666–4675CrossRef

20.

Tcyganov E, Mastio J, Chen E, Gabrilovich DI (2018) Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol 51:76–82. https://doi.org/10.1016/j.coi.2018.03.009 CrossRefPubMedPubMedCentral

21.

Moses K, Brandau S (2016) Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol 28(2):187–196. https://doi.org/10.1016/j.smim.2016.03.018 CrossRefPubMed

22.

Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, Masters JE, Rustin MH, Taams LS, Beverley PC, Macallan DC, Akbar AN (2006) Human CD4 + CD25hi Foxp3 + regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116(9):2423–2433. https://doi.org/10.1172/jci28941 CrossRefPubMedPubMedCentral

23.

Facciabene A, Motz GT, Coukos G (2012) T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72(9):2162–2171. https://doi.org/10.1158/0008-5472.Can-11-3687 CrossRefPubMedPubMedCentral

24.

Zhang X, Zhang W, Yuan X, Fu M, Qian H, Xu W (2016) Neutrophils in cancer development and progression: roles, mechanisms, and implications (Review). Int J Oncol 49(3):857–867. https://doi.org/10.3892/ijo.2016.3616 CrossRefPubMed

25.

Minami S, Ihara S, Komuta K (2018) Pretreatment lymphocyte to monocyte ratio as a prognostic marker for advanced pulmonary squamous cell carcinoma treated with chemotherapy. J Clin Med Res 10(8):657–664. https://doi.org/10.14740/jocmr3490w CrossRefPubMedPubMedCentral

26.

Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699. https://doi.org/10.1038/bjc.2012.292 CrossRefPubMedPubMedCentral

27.

Kim YJ, Lee I, Chung YS, Nam E, Kim S, Kim SW, Kim YT, Lee JY (2018) Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstet Gynecol Sci 61(2):227–234. https://doi.org/10.5468/ogs.2018.61.2.227 CrossRefPubMedPubMedCentral

28.

Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A (2018) Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 150(1):31–37. https://doi.org/10.1016/j.ygyno.2018.05.004 CrossRefPubMed

29.

Komura N, Mabuchi S, Yokoi E, Kozasa K, Kuroda H, Sasano T, Matsumoto Y, Kimura T (2018) Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review. Int J Clin Oncol 23(1):104–113. https://doi.org/10.1007/s10147-017-1180-4 CrossRefPubMed

30.

Zhou M, Li L, Wang X, Wang C, Wang D (2018) Neutrophil-to-lymphocyte ratio and platelet count predict long-term outcome of stage iiic epithelial ovarian cancer. Cell Physiol Biochem 46(1):178–186. https://doi.org/10.1159/000488420 CrossRefPubMed

31.

Buzzonetti A, Fossati M, Catzola V, Scambia G, Fattorossi A, Battaglia A (2014) Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial. Cancer Immunol Immunother 63(10):1037–1045. https://doi.org/10.1007/s00262-014-1569-0 CrossRefPubMed

32.

Schultes BC, Whiteside TL (2003) Monitoring of immune responses to CA125 with an IFN-g ELISPOT assay. J Immunol Methods 279:1–15. https://doi.org/10.1016/S0022-1759(03)00253-9 CrossRefPubMed

33.

Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S (2016) Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother 65(2):161–169. https://doi.org/10.1007/s00262-015-1782-5 CrossRefPubMedPubMedCentral

34.

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25(18):2546–2553. https://doi.org/10.1200/jco.2006.08.5829 CrossRefPubMed

35.

Wang PF, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX (2018) Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies. Oncoimmunology 7(10):e1494113. https://doi.org/10.1080/2162402x.2018.1494113 CrossRefPubMedPubMedCentral

36.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18(8):1254–1261. https://doi.org/10.1038/nm.2883 CrossRefPubMed

37.

Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B (2016) Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22(12):2908–2918. https://doi.org/10.1158/1078-0432.Ccr-15-2412 CrossRefPubMedPubMedCentral

38.

Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, de St Fazekas, Groth B (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203(7):1693–1700. https://doi.org/10.1084/jem.20060468 CrossRefPubMedPubMedCentral

39.

Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, de St Fazekas, Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med 203(7):1701–1711. https://doi.org/10.1084/jem.20060772 CrossRefPubMedPubMedCentral

40.

Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 7(12):e51862. https://doi.org/10.1371/journal.pone.0051862 CrossRefPubMedPubMedCentral

41.

Group F-NBW (2016) BEST (Biomarkers, EndpointS, and other Tools) resource [Internet]. understanding prognostic versus predictive biomarkers. Food and Drug Administration (US). Co-published by National Institutes of Health (US), Bethesda (MD). Silver Spring (MD)

42.

van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, van de Water B, Arens R, van der Burg SH, Melief CJ (2015) Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin Cancer Res 21(4):781–794. https://doi.org/10.1158/1078-0432.Ccr-14-2142 CrossRefPubMed

43.

Wang X, Liu Y, Diao Y, Gao N, Wan Y, Zhong J, Zheng H, Wang Z, Jin G (2018) Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil. J Transl Med 16(1):120. https://doi.org/10.1186/s12967-018-1501-z CrossRefPubMedPubMedCentral

44.

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28(6):690–714. https://doi.org/10.1016/j.ccell.2015.10.012 CrossRefPubMed

45.

Vacchelli E, Ma Y, Baracco EE, Zitvogel L, Kroemer G (2016) Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: formyl peptide receptor-1. Oncoimmunology 5(5):e1118600. https://doi.org/10.1080/2162402x.2015.1118600 CrossRefPubMedPubMedCentral

46.

Wu J, Waxman DJ (2018) Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett 419:210–221. https://doi.org/10.1016/j.canlet.2018.01.050 CrossRefPubMedPubMedCentral

47.

Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, Shtainberg H, Lotem M, Baniyash M (2016) Clinical significance of circulating CD33 + CD11b + HLA-DR- myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res 22(23):5661–5672. https://doi.org/10.1158/1078-0432.Ccr-15-3104 CrossRefPubMed

48.

Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015) Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunol Immunother 64(12):1609–1621. https://doi.org/10.1007/s00262-015-1766-5 CrossRefPubMed

49.

Ostrand-Rosenberg S, Fenselau C (2018) Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol 200(2):422–431. https://doi.org/10.4049/jimmunol.1701019 CrossRefPubMedPubMedCentral

50.

Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, Gabrilovich DI (2017) Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin Cancer Res 23(12):2942–2950. https://doi.org/10.1158/1078-0432.Ccr-16-1784 CrossRefPubMed

51.

Liu Y, Wei G, Cheng WA, Dong Z, Sun H, Lee VY, Cha SC, Smith DL, Kwak LW, Qin H (2018) Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunol Immunother 67(8):1181–1195. https://doi.org/10.1007/s00262-018-2175-3 CrossRefPubMed

52.

Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V (2018) Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol 9:398. https://doi.org/10.3389/fimmu.2018.00398 CrossRefPubMedPubMedCentral

53.

Clappaert EJ, Murgaski A, Van Damme H, Kiss M, Laoui D (2018) Diamonds in the rough: harnessing tumor-associated myeloid cells for cancer therapy. Front Immunol 9:2250. https://doi.org/10.3389/fimmu.2018.02250 CrossRefPubMedPubMedCentral

54.

Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK (2016) Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep 6:39247. https://doi.org/10.1038/srep39247 CrossRefPubMedPubMedCentral

55.

Xu T, Lu J, An H (2017) The relative change in regulatory T cells/T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients. Oncotarget 8(65):109079–109093. https://doi.org/10.18632/oncotarget.22606 CrossRefPubMedPubMedCentral

56.

Riemann D, Cwikowski M, Turzer S, Giese T, Grallert M, Schutte W, Seliger B (2019) Blood immune cell biomarkers in lung cancer. Clin Exp Immunol 195(2):179–189. https://doi.org/10.1111/cei.13219 CrossRefPubMed

57.

Bohm S, Montfort A, Pearce OMT, Topping J, Chakravarty P, Everitt GLA, Clear A, McDermott JR, Ennis D, Dowe T, Fitzpatrick A, Brockbank EC, Lawrence AC, Jeyarajah A, Faruqi AZ, McNeish IA, Singh N, Lockley M, Bohm FRB (2016) Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin Cancer Res 22(12):3025–3036. https://doi.org/10.1158/1078-0432.CCR-15-2657 CrossRefPubMed

58.

Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Palla G, Wöll E, Jamnig H, Gastl G, Wolf AM, Hilbe W, Wolf D (2014) Neoadjuvant chemo-immunotherapy modifies CD4 + CD25 + regulatoryT cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer 85:81–87. https://doi.org/10.1016/j.lungcan.2014.04.001 CrossRefPubMed

59.

Shoji SH, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T (2017) The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget 8(56):95083–95094. https://doi.org/10.18632/oncotarget.18297(eCollection 2017 Nov 10) CrossRefPubMedPubMedCentral

60.

Jiang T, Qiao M, Zhao C, Li X, Gao G, Su C, Ren S, Zhou C (2018) Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. Cancer Immunol Immunother 67(5):713–727. https://doi.org/10.1007/s00262-018-2126-z CrossRefPubMed

61.

Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 11:955–965. https://doi.org/10.2147/ott.S153290 CrossRefPubMedPubMedCentral

62.

Walankiewicz M, Grywalska E, Polak G, Kotarski J, Siwicka-Gieroba DJ, Rolinski J (2017) Myeloid-derived suppressor cells in ovarian cancer: friend or foe? Cent Eur J Immunol 42(4):383–389. https://doi.org/10.5114/ceji.2017.72823 CrossRefPubMedPubMedCentral

63.

Uribe-Querol E, Rosales C (2015) Neutrophils in cancer: two sides of the same coin. J Immunol Res 2015:983698. https://doi.org/10.1155/2015/983698 CrossRefPubMedPubMedCentral

64.

Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16(7):431–446. https://doi.org/10.1038/nrc.2016.52 CrossRef

65.

De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V (2010) Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 11(11):1039–1046. https://doi.org/10.1038/ni.1942 CrossRefPubMedPubMedCentral

66.

Zhou J, Nefedova Y, Lei A, Gabrilovich D (2018) Neutrophils and PMN-MDSC: their biological role and interaction with stromal cells. Semin Immunol 35:19–28. https://doi.org/10.1016/j.smim.2017.12.004 CrossRefPubMed

Titel: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients
verfasst von: Alessandra Battaglia
Alexia Buzzonetti
Marco Fossati
Giovanni Scambia
Andrea Fattorossi
Madi R. Madiyalakan
Yolanda D. Mahnke
Christopher Nicodemus
Publikationsdatum: 03.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 3/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02456-z

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies

Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie